dexmedetomidine has been researched along with Colitis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Xu, H; Xu, Y; Ye, X | 1 |
| Durmus, M; Erdogan Kayhan, G; Ersoy, MÖ; Gedik, E; Gul, M; Kayhan, B; Kurtoglu, EL; Ozgul, U | 1 |
2 other study(ies) available for dexmedetomidine and Colitis
| Article | Year |
|---|---|
Dexmedetomidine alleviates intestinal barrier dysfunction and inflammatory response in mice via suppressing TLR4/MyD88/NF-κB signaling in an experimental model of ulcerative colitis.
Topics: Animals; Colitis; Colitis, Ulcerative; Dexmedetomidine; Disease Models, Animal; Female; Fluorescein-5-isothiocyanate; Intestinal Mucosa; Mice; Mice, Inbred C57BL; Models, Theoretical; Myeloid Differentiation Factor 88; NF-kappa B; Toll-Like Receptor 4 | 2022 |
Dexmedetomidine ameliorates TNBS-induced colitis by inducing immunomodulator effect.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Cells, Cultured; Colitis; Cytokines; Dexmedetomidine; Disease Models, Animal; Dose-Response Relationship, Drug; Immune System; Immunomodulation; In Vitro Techniques; Male; Mice; Mice, Inbred BALB C; Spleen; Th17 Cells; Th2 Cells; Trinitrobenzenesulfonic Acid | 2013 |